Genitourinary Cancers | Clinical

Efficacy of Frontline Atezolizumab Combo Is Comparable Regardless of Primary Urothelial Cancer Location

January 23, 2021

An exploratory analysis of the phase 3 IMvigor130 trial demonstrated that the benefit of frontline atezolizumab added to gemcitabine and platinum chemotherapy was maintained in patients with urothelial cancer, regardless of the site of the primary tumor.

Experts Review Important Treatment Options in Urothelial Cancer

January 14, 2021

During a Targeted Oncology Case-Based Peer Perspectives Roundtable, two Mayo Clinic experts, Alan H. Bryce, MD, and Roxana S. Dronca, MD, discuss treatment options for a 66-year-old woman with urothelial carcinoma.

Frontline Maintenance Therapy for Urothelial Cancer Emerges

December 30, 2020

After decades of dormancy, the therapeutic landscape of locally advanced/metastatic urothelial cancer underwent a paradigm shift—with multiple regulatory approvals of immune checkpoint inhibitors as second-line treatment—leading to changes in guideline-recommended management of patients in this setting.

Deciding on an Agent for Prostate Cancer Involves Careful Consideration of Prior Therapy

December 28, 2020

Anthony A. Meluch, MD, medical oncologist, Tennessee Oncology, discussed treatment options for high-risk adenocarcinoma of the prostate based on the case of a 75-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.

Countless Options to Improve Future Outcomes in Subgroups of Patients With GU Cancers

October 30, 2020

In genitourinary cancers, presentation of subgroup analysis data from large randomized clinical trials demonstrated findings that will change practice for oncologists who treat patients with prostate cancer, bladder cancer, and renal cell carcinoma.